Mylan Launches Generic Angiomax® Injection
Summary
Bivalirudin for Injection, 250 mg single-dose vial, had U.S. sales of approximately $106 million for the 12 months ending March 31, 2018, according to IQVIA.Currently, Mylan has 199 ANDAs pending FDA approval representing approximately $88.5 billion in annual brand sales, according to IQVIA.Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $45.5 billion in annual brand sales, for the 12 months ending December 31, 2017, according to IQVIA.Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do whats right, not whats easy; and impact the future through passionate global leadership.We offer a growing portfolio of more than 7,500 marketed products around the world, including antiretroviral therapies on which more than 40% of people being treated for HIV/AIDS globally depend.